Form 4: Neogenomics Chief Accounting Officer Greg D. Aunan Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Greg D. Aunan, Chief Accounting Officer of Neogenomics Inc., reports the grant of stock options and restricted stock units on February 21, 2025.
Summary
- This Form 4 filing reports changes in beneficial ownership for Greg D. Aunan, Chief Accounting Officer of Neogenomics Inc.
- On February 21, 2025, Mr. Aunan was granted 31,163 stock options exercisable at $11.86, vesting ratably over three years.
- Also on February 21, 2025, he received 18,971 restricted stock units, vesting ratably over three years.
- Mr. Aunan also holds previously granted stock options: 28,662 options granted on May 1, 2023, exercisable at $14.62, and 26,978 options granted on May 2, 2024, exercisable at $13.96.
- He also holds 16,117 restricted stock units granted on May 2, 2024.
- Following these transactions, Mr. Aunan directly owns 14,453 shares of common stock, 31,163 new stock options, 18,971 new restricted stock units, 28,662 stock options from May 1, 2023, 26,978 stock options from May 2, 2024, and 16,117 restricted stock units from May 2, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grants align management interests with shareholders, which is generally viewed favorably.
Positives
- The grant of stock options and restricted stock units aligns Mr. Aunan's interests with those of the shareholders, incentivizing him to improve company performance.
- The vesting schedules encourage long-term commitment from Mr. Aunan.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology and diagnostics industries, aligning management incentives with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded companies like Neogenomics and its competitors such as Exact Sciences and Guardant Health.
- The vesting schedules and exercise prices are generally structured to incentivize long-term performance and retention of key personnel.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize management to improve company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 05/01/2023 | Mr. Aunan was granted 28,662 stock options. |
| 05/02/2024 | Mr. Aunan was granted 26,978 stock options and 16,117 restricted stock units. |
| 02/21/2025 | Mr. Aunan was granted 31,163 stock options and 18,971 restricted stock units. |
| 02/25/2025 | Date of the Form 4 filing. |
| 05/01/2030 | Expiration date for the stock options granted on May 1, 2023. |
| 05/02/2034 | Expiration date for the stock options granted on May 2, 2024. |
| 02/21/2035 | Expiration date for the stock options granted on February 21, 2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.